口服祛痰藥市場 - 按藥物類型、劑型、藥物、配銷通路- 全球預測

由於全球氣喘、慢性支氣管炎和COPD（慢性阻塞性肺病）等呼吸系統疾病的盛行率不斷上升，口服祛痰藥市場規模預計在2024 年至2032 年期間複合年成長率將達到創紀錄的3.4 %。根據世界衛生組織的數據，目前全球有 3.92 億人患有慢性阻塞性肺病。這些情況可能會引起咳嗽和產生黏液等症狀，進一步增加了對口服避孕藥作為常見治療選擇的需求。此外，由於空氣污染、吸菸和生活方式的改變，呼吸系統疾病的風險不斷增加，有利於產品的採用。

隨著人口老化的加劇和呼吸系統疾病的增加，對口腔呼吸器的需求日益加劇。醫療保健基礎設施的快速進步以及藥房和線上平台上非處方藥（OTC）的可用性的提高也將為獲得口服前景提供機會，從而支持市場成長。

口腔祛痰藥產業分為藥物類型、劑型、用藥、配銷通路和區域。

根據藥物類型，黏液溶解劑領域的市場規模在2024年至2032年間將錄得3.1%的成長率，因為它能有效治療慢性支氣管炎和囊性纖維化等以黏液黏稠為特徵的呼吸道疾病。黏液溶解劑有助於稀釋和鬆弛黏液分泌物，使人們在咳嗽時更容易清理呼吸道。這種操作方法還可以減少胸悶和呼吸困難等症狀，增加患者對黏液溶解劑的需求，同時為醫療專業人員提供建議。

就配銷通路而言，預計2024年至2032年，線上藥局領域的口服祛痰藥市場複合年成長率將達到2.9%，這得益於消費者可以方便地獲得各種祛痰藥物。隨著感染和呼吸道疾病（例如咳嗽和流鼻涕）的增加，口腔診所可以幫助患者輕鬆獲得非處方祛痰產品。此外，藥劑師更常提供有關適當祛痰劑選擇的建議和指導將增加消費者的信心和產品的使用。

至2032年，由於都市化、工業化和環境污染，亞太地區口服祛痰藥產業規模將以4%的複合年成長率持續成長。人口眾多、呼吸健康意識不斷增強以及醫療保健服務的普及將推動產品的採用。可滿足區域需求和監管系統的各種口服祛痰劑配方也促進了亞太地區的市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 呼吸道疾病盛行率增加
    • 對非處方藥的需求不斷成長
    • 老年人口不斷增加
    • 提高人們對呼吸系統疾病的認知
  • 產業陷阱與挑戰
    • 嚴格的政府和監管指南
• 成長潛力分析
• 管道分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

• 主要趨勢
• 分泌促進劑
  • 檸檬酸鉀
  • 碘化鉀
  • 檸檬酸鈉
  • 癒創甘油醚
  • 氯化銨
  • 其他分泌促進劑
• 黏液溶解劑
  • 溴己新
  • 氨溴索
  • 乙醯半胱氨酸
  • 羧甲司坦神經氨酸

第 6 章：市場估計與預測：按劑型，2021 - 2032

• 主要趨勢
• 口服固體製劑
  • 粉末及顆粒
  • 藥片
  • 膠囊
• 口服液
  • 糖漿
  • 解決方案
  • 暫停
• 吸入劑

第 7 章：市場估計與預測：按藥物分類，2021 - 2032 年

• 主要趨勢
• 處方藥
• 非處方藥物

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售店和藥局
• 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要動向：按地區
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 10 章：公司簡介

• Abbott Laboratories
• AstraZeneca
• Cipla Inc.
• Genexa Inc.
• GlaxoSmithKline (GSK) plc
• Merck KGaA
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• The Himalaya Drug Company

Oral expectorant market size is set to record 3.4% CAGR from 2024 to 2032, driven by the increasing prevalence of respiratory diseases, such as asthma, chronic bronchitis, and COPD (Chronic Obstructive Pulmonary Disease) worldwide. As per WHO, currently 392 million people suffer from COPD worldwide. These conditions can cause symptoms like cough and mucus production, further increasing the need for oral contraceptives as a common treatment option. Moreover, the risk of respiratory diseases is increasing due to air pollution, smoking and lifestyle changes, favoring the product adoption.

With the growing aging population and increasing respiratory diseases, the need for oral ventilators is intensifying. Rapid advancements in healthcare infrastructure and higher availability of over the counter (OTC) drugs in pharmacies and online platforms will also provide opportunities to access oral prospects, supporting the market growth.

The oral expectorant industry is segmented into drug type, dosage form, medication, distribution channel, and region.

Based on drug type, the market size from the mucolytics segment will record 3.1% growth rate between 2024 and 2032, due to its efficiency in treating respiratory conditions characterized by thick and tenacious mucus, such as chronic bronchitis and cystic fibrosis. Mucolytics help thin and loosen mucous secretions, making it easier for people to clear their airways when they cough. This method of operation also reduces symptoms, such as chest congestion and dyspnea for increasing the patients need for mucolytics while providing recommendations for healthcare professionals.

With regards to distribution channel, the oral expectorant market from the online pharmacies segment is anticipated to witness 2.9% CAGR from 2024-2032, favored by convenient access to a wide range of expectorant medications for consumers. With the increase in infections and respiratory diseases, such as cough and runny nose, oral medicine clinics help in providing patients with easy access to over-the-counter expectorant products. Furthermore, increased availability of pharmacists for advice and guidance on appropriate expectorant choices will increase consumer confidence and product use.

Asia Pacific oral expectorant industry size will record sustained growth at 4% CAGR through 2032, attributed to urbanization, industrialization, and environmental pollution. Large population, increasing awareness about respiratory health and strong access to healthcare services will drive the product adoption. The wide variety of oral expectorant formulations available to meet regional needs and regulatory systems is also contributing to the market growth in APAC.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory disease
    • 3.2.1.2 Growing demand for OTC medications
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Increasing awareness among people about respiratory conditions
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Strict government and regulatory guidelines
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Secretion enhancer
  • 5.2.1 Potassium citrate
  • 5.2.2 Potassium iodide
  • 5.2.3 Sodium citrate
  • 5.2.4 Guaiphenesin
  • 5.2.5 Ammonium chloride
  • 5.2.6 Other secretion enhancer
• 5.3 Mucolytics
  • 5.3.1 Bromhexine
  • 5.3.2 Ambroxol
  • 5.3.3 Acetyl cysteine
  • 5.3.4 Carbocisteineurine

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral solids
  • 6.2.1 Powder & granules
  • 6.2.2 Tablet
  • 6.2.3 Capsule
• 6.3 Oral liquids
  • 6.3.1 Syrup
  • 6.3.2 Solution
  • 6.3.3 Suspension
• 6.4 Inhalants

Chapter 7 Market Estimates and Forecast, By Medication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Prescription drugs
• 7.3 Over-the-counter drugs

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail store & drug store
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AstraZeneca
• 10.3 Cipla Inc.
• 10.4 Genexa Inc.
• 10.5 GlaxoSmithKline (GSK) plc
• 10.6 Merck KGaA
• 10.7 Perrigo Company plc
• 10.8 Reckitt Benckiser Group PLC
• 10.9 Sanofi
• 10.10 Sun Pharmaceutical Industries Ltd.
• 10.11 The Himalaya Drug Company